Evidence map›Paper›PMID 29371644›Full record

ArticleThe Journal of antibiotics2018

Recombinant yeast and human cells as screening tools to search for antibacterial agents targeting the transcription termination factor Rho.

Kévin Moreau, Justine Surand, Aurélia Le Dantec, Christine Mosrin-Huaman, Alain Legrand, A Rachid Rahmouni

Open access · hybridAbstract read
In one paragraph

Article in The Journal of antibiotics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Kévin MoreauCentre de Biophysique Moléculaire, UPR 4301 du CNRS, Rue Charles Sadron, 45071, Orléans, France.
Justine SurandCentre de Biophysique Moléculaire, UPR 4301 du CNRS, Rue Charles Sadron, 45071, Orléans, France.
Aurélia Le DantecCentre de Biophysique Moléculaire, UPR 4301 du CNRS, Rue Charles Sadron, 45071, Orléans, France.
Christine Mosrin-HuamanCentre de Biophysique Moléculaire, UPR 4301 du CNRS, Rue Charles Sadron, 45071, Orléans, France.
Alain LegrandUniversity of Orléans, Pole Universitaire Centre Val de Loire, Orléans, France.
A Rachid RahmouniCentre de Biophysique Moléculaire, UPR 4301 du CNRS, Rue Charles Sadron, 45071, Orléans, France. rahmouni@cnrs-orleans.fr.
Centre de Biophysique Moléculaire · FRCentre National de la Recherche Scientifique · FRUniversité d'Orléans · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The alarming issue of antibiotic resistance expansion requires a continuous search for new and efficient antibacterial agents. Here we describe the design of new tools to screen for target-specific inhibitors of the bacterial Rho factor directly inside eukaryotic cells. Rho factor is a global regulator of gene expression which is essential to most bacteria, especially Gram-negative. Since Rho has no functional or structural homolog in eukaryotes, it constitutes a valuable and well known bacterial target as evidenced by its inhibition by the natural antibiotic, Bicyclomycin. Our screening tools are based on perturbation of mRNA processing and packaging reactions in the nucleus of eukaryotic cells by the RNA-dependent helicase/translocase activity of bacterial Rho factor leading to a growth defect phenotype. In this approach, any compound that impedes Rho activity should restore growth to yeast or human cells expressing Rho protein, providing valuable means to screen for target-specific antibacterial agents within the environment of a eukaryotic cell. The yeast tool expressing E. coli Rho factor was validated using Bicyclomycin as the control antibacterial agent. The validation of the screening tool was further extended with a stable human cell line expressing Rho factor conditionally. Finally, we show that Rho factors from different bacterial pathogens can also be designed as yeast-based screening tools which can reveal subtle variations in the functional features of the proteins.

Indexed as

Anti-Bacterial AgentsBacterial InfectionsCell LineCell SurvivalDrug Evaluation, PreclinicalEscherichia coliGram-Negative BacteriaHEK293 CellsHumansRho FactorSaccharomyces cerevisiaeTranscription, GeneticYeastsAnti-Bacterial AgentsRho Factor

Identifiers

PMID29371644
PMCPMC5869860
OpenAlexW2792793497

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.